tiprankstipranks
Ocular Therapeutix Inc (OCUL)
NASDAQ:OCUL
US Market
OCUL
Ocular Therapeutix
RESEARCH TOOLSreports
Want to see OCUL full AI Analyst Report?

Ocular Therapeutix (OCUL) Stock News & Sentiment

1,590 Followers
Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks
Premium
Company Announcements
Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks
12d ago
OCUL
Analyst Reiterates Buy Rating on OCUL, Keeps Axpaxli-Driven Price Target Unchanged at $18
Premium
Ratings
Analyst Reiterates Buy Rating on OCUL, Keeps Axpaxli-Driven Price Target Unchanged at $18
13d ago
OCUL
Axpaxli’s Strong Phase III Data and Favorable FDA Path Support Buy Rating and Unchanged $20 Price Target
Premium
Ratings
Axpaxli’s Strong Phase III Data and Favorable FDA Path Support Buy Rating and Unchanged $20 Price Target
13d ago
OCUL
Analyst Reiterates Buy on Axpaxli Ahead of NDA Filing and Key SOL-R/SOL-X Data Catalysts
Premium
Ratings
Analyst Reiterates Buy on Axpaxli Ahead of NDA Filing and Key SOL-R/SOL-X Data Catalysts
13d ago
OCUL
Ocular Therapeutix Inc (OCUL) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
Ocular Therapeutix Inc (OCUL) Q1 Earnings Cheat Sheet
15d ago
OCUL
OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target
Premium
Ratings
OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target
3M ago
OCUL
Axpaxli’s Superior SOL-1 Phase 3 Data Support Buy Rating and Constructive Outlook on Ocular Therapeutix
Premium
Ratings
Axpaxli’s Superior SOL-1 Phase 3 Data Support Buy Rating and Constructive Outlook on Ocular Therapeutix
3M ago
OCUL
More OCUL News >

OCUL News on the Web

3 Stocks Under $10 That Fall Short
stockstory
Bearish
Ocular Therapeutix Stock Sinks as Growth Hopes Fade
TipRanks News
Bearish
Ocular Therapeutix (OCUL) Gets a Buy from Chardan Capital
TipRanks News
Bearish
Ocular Therapeutix (OCUL) Gets a Buy from RBC Capital
TipRanks News
Neutral
Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks
TipRanks News
Bearish
Analyst Reiterates Buy Rating on OCUL, Keeps Axpaxli-Driven Price Target Unchanged at $18
TipRanks News
Bullish
Axpaxli’s Strong Phase III Data and Favorable FDA Path Support Buy Rating and Unchanged $20 Price Target
TipRanks News
Neutral
Analyst Reiterates Buy on Axpaxli Ahead of NDA Filing and Key SOL-R/SOL-X Data Catalysts
TipRanks News
Bullish

News Score - Last 7 Days

Very Negative
OCUL
Sector Average
Media Buzz
This Week2 articles
Weekly Average3.5 articles
News Sentiment
This Week0%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is OCUL’s Media Buzz Sentiment?
2 articles about OCUL were published this week. In an average week, 3.5 articles are published.
    What is OCUL’s weekly average amount of articles?
    In an average week, 3.5 articles about OCUL are published.
      What is OCUL’s News Sentiment?
      Currently, no data Available
      Healthcare Stocks that are Trending in the News
      TVTXTravere Therapeutics
      HVOOpen Orphan Plc
      PBMPsyence Biomedical
      QDELQuidelOrtho
      Showing the stocks with the most bullish news sentiment over the past week